Lok-Hei Chan

Lok-Hei Chan

Auto-generated profile, based on publicly available information

Lok-Hei Chan

Department of Pathology, Yale School of Medicine, New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
MZMeiling Zhang
Meiling Zhang
ZLZongzhi Z. Liu
Zongzhi Z. Liu
KAKeisuke Aoshima
Keisuke Aoshima
WCWesley Lam Cai
Wesley Lam Cai
HSHongyin Sun
Hongyin Sun
Qin YanQin Yan
Qin Yan
Metastasis is the major cause of cancer-related deaths due to the lack of effective therapies. Emerging evidence suggests that certain epigenetic and transcriptional regulators drive cancer metastasis and could be targeted for metastasis treatment. To identify epigenetic regulators of breast cancer metastasis, we profiled the transcriptomes of matched pairs of primary breast tumors and metastases from human patients. We found that distant metastases are more immune inert with increased M2 macrophages compared to their matched primary tumors. The acetyl-lysine reader, cat eye syndrome chromosome region candidate 2 (CECR2), was the top up-regulated epigenetic regulator in metastases associated with an increased abundance of M2 macrophages and worse metastasis-free survival. CECR2 was required for breast cancer metastasis in multiple mouse models, with more profound effect in the immunocompetent setting. Mechanistically, the nuclear factor κB (NF-κB) family member v-rel avian reticuloendotheliosis viral oncogene homolog A (RELA) recruits CECR2 to increase chromatin accessibility and activate the expression of their target genes. These target genes include multiple metastasis-promoting genes, such as TNC , MMP2 , and VEGFA , and cytokine genes CSF1 and CXCL1 , which are critical for immunosuppression at metastatic sites. Consistent with these results, pharmacological inhibition of CECR2 bromodomain impeded NF-κB–mediated immune suppression by macrophages and inhibited breast cancer metastasis. These results reveal that targeting CECR2 may be a strategy to treat metastatic breast cancer.

1 March 2021 in Cancer Letters
Verified
Journal Article
Closed access
NCNoélia Che
Noélia Che
KNKai-Yu Ng
Kai-Yu Ng
TWTin-Lok Wong
Tin-Lok Wong
MTMan Tong
Man Tong
PKPhillis Wf. Kau
Phillis Wf. Kau
SMStephanie KY Ma
Stephanie KY Ma

15 February 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
BHBomiao Hu
Bomiao Hu
Marc WiesehöferMarc Wiesehöfer
Marc Wiesehöfer
FMFernando J. de Miguel
Fernando J. de Miguel
ZLZongzhi Liu
Zongzhi Liu
LCLok-Hei Chan
Lok-Hei Chan
KPKaterina Politi
Katerina Politi
The majority of EGFR mutant lung adenocarcinomas respond well to EGFR tyrosine kinase inhibitors (TKI). However, most of these responses are partial, with drug-tolerant residual disease remaining even at the time of maximal response. This residual disease can ultimately lead to relapses, which eventually develop in most patients. To investigate the cellular and molecular properties of residual tumor cells in vivo, we leveraged patient-derived xenograft (PDX) models of EGFR mutant lung cancer. Subcutaneous EGFR mutant PDXs were treated with the third-generation TKI osimertinib until maximal tumor regression. Residual tissue inevitably harbored tumor cells that were transcriptionally distinct from bulk pretreatment tumor. Single-cell transcriptional profiling provided evidence of cells matching the profiles of drug-tolerant cells present in the pretreatment tumor. In one of the PDXs analyzed, osimertinib treatment caused dramatic transcriptomic changes that featured upregulation of the neuroendocrine lineage transcription factor ASCL1. Mechanistically, ASCL1 conferred drug tolerance by initiating an epithelial-to-mesenchymal gene-expression program in permissive cellular contexts. This study reveals fundamental insights into the biology of drug tolerance, the plasticity of cells through TKI treatment, and why specific phenotypes are observed only in certain tumors. Significance: Analysis of residual disease following tyrosine kinase inhibitor treatment identified heterogeneous and context-specific mechanisms of drug tolerance in lung cancer that could lead to the development of strategies to forestall drug resistance. See related commentary by Rumde and Burns, p. 1188

15 April 2024
Verified
Other
Open access
PDF file
BHBomiao Hu
Bomiao Hu
Marc WiesehöferMarc Wiesehöfer
Marc Wiesehöfer
FMFernando J. de Miguel
Fernando J. de Miguel
ZLZongzhi Liu
Zongzhi Liu
LCLok-Hei Chan
Lok-Hei Chan
KPKaterina Politi
Katerina Politi
Characterization of mutant EGFR lung cancer PDXs at single-cell resolution. Workflow for scRNA-seq on PDXs and single cell data for an additional PDX.

15 April 2024
Verified
Other
Open access
BHBomiao Hu
Bomiao Hu
Marc WiesehöferMarc Wiesehöfer
Marc Wiesehöfer
FMFernando J. de Miguel
Fernando J. de Miguel
ZLZongzhi Liu
Zongzhi Liu
LCLok-Hei Chan
Lok-Hei Chan
KPKaterina Politi
Katerina Politi
Upregulated pathways in EGFR mutant cell lines transfected with ASCL1

15 April 2024
Verified
Other
Open access
PDF file
BHBomiao Hu
Bomiao Hu
Marc WiesehöferMarc Wiesehöfer
Marc Wiesehöfer
FMFernando J. de Miguel
Fernando J. de Miguel
ZLZongzhi Liu
Zongzhi Liu
LCLok-Hei Chan
Lok-Hei Chan
KPKaterina Politi
Katerina Politi
Changes in chromatin accessibility in HCC827 and PC9 cells upon ASCL1 expression. Global changes in chromatin accessibility in mutant EGFR lung cancer cell lines following ASCL1 overexpression and osimertinib treatment.